Abstract:
The molecular mechanism of retroviral mediated immunosuppression was characterized by testing the effect of synthetic, recombinant and native retroviral transmembrane polypeptides on several aspects of immune function. By use of synthetic peptides the minimum amino acid (aa) sequence required for inhibition of lymphoproliferation was determined to be an 8 aa sequence that is highly conserved among retroviruses including gp21 and gp41, the transmembrane proteins of human T lymphotropic virus type I/II (HTLV-I/II) and human immunodeficiency virus type 1 (HIV-1), respectively. A peptide containing the highly conserved sequence aa581-597 of HIV-1 gp41 inhibited both human and murine lymphoproliferation in vitro in addition to interleukin 2 (IL 2) production and the induction of IL 2 receptor expression. The activity of aa581-597 was dependent upon internalization and was irreversible. The molecular mechanism was characterized by showing that aa581-597 inhibits the cytoplasmic free Ca++ influx in T lymphocytes stimulated via the CD3/T cell antigen receptor complex at a site distal to inositol triphosphate production. aa581-597 was shown further to inhibit protein kinase C (pkC)-dependent phosphorylation of the CD3 gamma-chain in intact cells and to directly inhibit partially purified pkC. The inhibitory activity was confirmed in vivo; aa581-597 and the recombinant gp41 and p15E proteins inhibited the recruitment of macrophages to sites of delayed inflammatory response in mice after systemic administration of doses that reflected the antigen load present during infection. The immunosuppressive activities observed here for HIV-1 aa581-597 are consistent with the immune defects observed in HIV-1 infected individuals; these results suggest that the transmembrane protein gp41 and HIV-1 may inhibit pkC and thus block pkC-dependent immune function contributing to the immunosuppression of HIV-1 infected individuals. Studies were also carried out to assess the stability and tumor targeting of radioimmunoconjugates generated by coupling antibody with bifunctional chelating agents into which radioactive bismuth was incorporated. Furthermore, experiments were performed to correlate the physical characteristics of synthetic peptide proteosome vaccines with their immunogenic potency. (Full text available from University Microfilms International, Ann Arbor, MI, as Order No. AAD90-30242)
Keywords: Acquired Immunodeficiency Syndrome/GENETICS/*IMMUNOLOGY Amino Acid Sequence Animal Antigens, CD/IMMUNOLOGY Cells, Cultured Human HIV Envelope Protein gp41/GENETICS/IMMUNOLOGY HIV-1/GENETICS/*IMMUNOLOGY HTLV-I/GENETICS/IMMUNOLOGY HTLV-II/GENETICS/IMMUNOLOGY *Immunosuppression Mice Protein Kinase C/ANTAGONISTS & INHIB Recombinant Proteins/GENETICS/IMMUNOLOGY T-Lymphocytes/*IMMUNOLOGY/METABOLISM Viral Vaccines/IMMUNOLOGY THESIS 910430
M9140688
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.
